Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Oct 27;10(10):72. doi: 10.1038/s41389-021-00361-8

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021, corrected publication 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 4 — A Heatmap showing molecular subtype marker expression in proneural GSCs (PN12, PN16, and PN19), mesenchymal GSCs (ME23, ME27, and ME29), and proneural (or mesenchymal) GSCs infected with the indicated plasmids or shRNA or treated with the indicated inhibitors. HIF-1α inhibitor, GN44028, 12.5 μM. Palmitoylation inhibitor, 2-BP, 100 μM. Smad3 inhibitor, (E)-SIS3, 20 μM. EP300 inhibitor, C646, 15 μM. Z-scores were calculated from the △Ct values obtained in the quantitative polymerase chain reaction analysis. B Viability of proneural PN12 GSCs transfected with the indicated plasmids or shRNA or treated with GN44028, C646, 2-BP, or (E)-SIS3 for 48 h. C A serial dilution assay was used to determine the self-renewal capacity of PN12 GSCs transfected with the indicated plasmids or shRNA or treated with GN44028, C646, 2-BP, or (E)-SIS3. D Viability of mesenchymal ME23 GSCs transfected with the indicated plasmids or shRNA or treated with GN44028, C646, 2-BP, or (E)-SIS3 for 48 h. E A serial dilution assay was used to determine the self-renewal capacity of ME23 GSCs transfected with the indicated plasmids or shRNA or treated with GN44028, C646, 2-BP, or (E)-SIS3. GSCs glioblastoma stem cells, HIF-1α hypoxia-inducible factor 1-alpha.